Suchergebnisse - "Lauseker, Michael"

PubPharm (6)

1

How to individualize therapy after failing milestones in chronic myeloid leukaemia : weighting late response and early death from CML against risk of alternative therapies

enthalten in: Leukemia | 2024

von Hehlmann, R. | Lauseker, M.

CommentOn: Leukemia. 2023 Nov;37(11):2324-2325. - PMID 37798329

2

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)

enthalten in: Leukemia | 2022

von Hehlmann, R. | Lauseker, M. | Voskanyan, A. | +4

3

Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia

enthalten in: American journal of hematology | 2021

von Rautenberg, C. | Germing, U. | Stepanow, S. | +8

4

Reply to H. Kantarjian et al

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2014

von Hehlmann, R. | Hasford, J. | Pfirrmann, M. | +5

CommentOn: J Clin Oncol. 2014 Feb 10;32(5):415-23. - PMID 24297946

5

Remission status should not be treated as a base-line covariate--reply to Etienne et al

enthalten in: Haematologica | 2014

von Lauseker, M. | Hasford, J.

CommentOn: Haematologica. 2014 Mar;99(3):458-64. - PMID 24362549

6

Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82

enthalten in: Haematologica | 2012

von Lauseker, M. | Pfirrmann, M. | Hoffmann, V. | +1

CommentOn: Haematologica. 2011 Dec;96(12):1779-82. - PMID 21859733

1
[1]